Stanford inventors have developed a single cell screening platform that can be used to predict the therapeutic effects of osteoarthritis (OA) drugs on individual patients by defining consequent changes in the cellular landscape.
Researchers at Stanford have discovered that treatment with JNK II inhibitor and IBMX has a synergistic therapeutic effect against osteoarthritis (OA).